SCHEMBL1002032

SCHEMBL1002032

COc1c(F)c(F)c(C(N)=O)c(F)c1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.41
MEN1 O00255 5/20 0.41
CYP2C9 P11712 2/20 0.41
CYP1A2 P05177 1/20 0.41
POLB P06746 4/20 0.38
KDM4E B2RXH2 3/20 0.38
TSHR P16473 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
GFER P55789 1/20 0.38
PTPN1 P18031 1/20 0.35
APOBEC3A P31941 1/20 0.35
HTT P42858 1/20 0.35
APOBEC3G Q9HC16 1/20 0.35
CTDSP1 Q9GZU7 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34
PARP1 P09874 1/20 0.34
PARP10 Q53GL7 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24767323 0.86 MEN1 (0.34) KMT2AMEN1CYP2C9CYP1A2POLB
SCHEMBL28098838 0.81 HSD17B10 (0.40) KMT2APOLBKDM4ETSHRSMN1; SMN2
SCHEMBL811680 0.80 POLB (0.41) KMT2AMEN1POLBTSHRSMN1; SMN2
SCHEMBL5702932 0.79 MEN1 (0.54) KMT2AMEN1CYP2C9CYP1A2POLB
SCHEMBL14486685 0.79 KMT2A (0.42) KMT2AMEN1CYP2C9CYP1A2POLB
SCHEMBL10339638 0.77 KMT2A (0.41) KMT2AMEN1CYP2C9CYP1A2POLB
SCHEMBL29154296 0.77 MEN1 (0.53) KMT2AMEN1CYP2C9CYP1A2POLB
SCHEMBL8464230 0.77 KMT2A (0.53) KMT2AMEN1CYP2C9CYP1A2POLB
SCHEMBL9766076 0.77 TSHR (0.52) KMT2AMEN1CYP2C9CYP1A2POLB
SCHEMBL28298959 0.77 POLB (0.39) KMT2AMEN1POLBHTTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115043774-B Synthesis method of fluoroether bacteria amide 山东省农药检定所 2024-07-23 CN disclosed
US-20240226255-A9 COMPOSITIONS AND METHODS FOR ACTIVATING NK CELLS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2024-07-11 US disclosed
US-20240131130-A1 COMPOSITIONS AND METHODS FOR ACTIVATING NK CELLS UNIV CALIFORNIA (US) 2024-04-25 US disclosed
CN-115015425-B Method for determining fluoroether bacteria amide residues in red sage root by combining solid phase extraction with UPLC-MS/MS 山东省农业科学院 2024-02-23 CN disclosed
CN-115097088-B Toxicity evaluation method of fluoroether bacteria amide 山东农业大学 2024-02-13 CN disclosed
EP-4310504-A2 ACTIVITY-BASED PROBE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE The Board of Trustees of the Leland Stanford Junior University (US) 2024-01-24 EP disclosed
CN-115039783-B Sterilization composition, preparation method and application thereof 东莞市东阳光农药研发有限公司 2024-01-16 CN disclosed
EP-4294414-A1 COMPOSITIONS AND METHODS FOR ACTIVATING NK CELLS The Regents of The University of California (US) 2023-12-27 EP disclosed
EP-3510380-B1 ACTIVITY-BASED PROBE COMPOUNDS, COMPOSITIONS, AND METHODS OF USE UNIV LELAND STANFORD JUNIOR (US) 2023-11-08 EP disclosed
EP-3681504-B1 METHODS OF DETECTION USING X-RAY FLUORESCENCE ICAGEN INC (US) 2023-08-23 EP disclosed
US-20130338389-A1 IONIC LIQUIDS FOR SEPARATION OF OLEFIN-PARAFFIN MIXTURES UT-BATTELLE, LLC (US) 2013-12-19 US disclosed
US-8535560-B2 Ionic liquids for separation of olefin-paraffin mixtures UT-BATTELLE, LLC (US) 2013-09-17 US disclosed
EP-2511844-A2 Advanced drug development and manufacturing Los Alamos National Security, LLC (US) 2012-10-17 EP disclosed
EP-2084519-B1 X-RAY FLUORESCENCE ANALYSIS METHOD LOS ALAMOS NAT SECURITY LLC (US) 2012-08-01 EP disclosed
WO-2011008664-A2 IONIC LIQUIDS FOR SEPARATION OF OLEFIN-PARAFFIN MIXTURES UT-BATTELLE, LLC (US) 2011-01-20 WO disclosed
US-20110015461-A1 Ionic Liquids for Separation of Olefin-Paraffin Mixtures UT-BATTELLE, LLC (US) 2011-01-20 US disclosed
EP-2084519-A2 ADVANCED DRUG DEVELOPMENT AND MANUFACTURING Los Alamos National Security, LLC (US) 2009-08-05 EP disclosed
WO-2008127291-A2 ADVANCED DRUG DEVELOPMENT AND MANUFACTURING LOS ALAMOS NATIONAL SECURITY, LLC (US) 2008-10-23 WO disclosed
US-20080220441-A1 Advanced drug development and manufacturing THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2008-09-11 US disclosed
US-5360819-A Nonradioactive labels which provide a ketone signal, vapor phase analysis NORTHEASTERN UNIVERSITY (US) 1994-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130338389-A1 IONIC LIQUIDS FOR SEPARATION OF OLEFIN-PARAFFIN MIXTURES POU2F1, POU2F2, POF1B KMT2A 3578/4885MEN1 1717/4885CYP2C9 2348/4885
US-20110015461-A1 Ionic Liquids for Separation of Olefin-Paraffin Mixtures POU2F1, POU2F2, POF1B KMT2A 3578/4885MEN1 1717/4885CYP2C9 2348/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.